Transcat, Inc. (NASDAQ:TRNS) saw a significant decline in short interest in May. As of May 31st, there was short interest totalling 28,400 shares, a decline of 9.3% from the April 30th total of 31,300 shares. Approximately 0.4% of the shares of the stock are short sold. Based on an average trading volume of 21,900 shares, the short-interest ratio is currently 1.3 days.
Shares of TRNS traded up $0.18 during mid-day trading on Friday, reaching $25.30. The company’s stock had a trading volume of 38,162 shares, compared to its average volume of 82,742. The firm has a market capitalization of $184.69 million, a PE ratio of 26.63, a PEG ratio of 3.02 and a beta of 0.74. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.39 and a current ratio of 2.03. Transcat has a 52 week low of $17.56 and a 52 week high of $27.00. The stock’s fifty day moving average price is $25.25.
Transcat (NASDAQ:TRNS) last announced its quarterly earnings data on Tuesday, May 21st. The scientific and technical instruments company reported $0.35 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.26 by $0.09. The firm had revenue of $44.49 million during the quarter, compared to analyst estimates of $41.90 million. Transcat had a net margin of 4.44% and a return on equity of 12.77%. As a group, sell-side analysts expect that Transcat will post 1.04 EPS for the current fiscal year.
Several hedge funds and other institutional investors have recently modified their holdings of TRNS. Marshall Wace North America L.P. boosted its stake in Transcat by 157.5% in the 1st quarter. Marshall Wace North America L.P. now owns 1,545 shares of the scientific and technical instruments company’s stock worth $36,000 after purchasing an additional 945 shares in the last quarter. Oppenheimer Asset Management Inc. bought a new position in Transcat during the 1st quarter valued at about $62,000. Howe & Rusling Inc. lifted its stake in Transcat by 40.4% during the 1st quarter. Howe & Rusling Inc. now owns 6,950 shares of the scientific and technical instruments company’s stock valued at $160,000 after acquiring an additional 2,000 shares during the period. Bank of New York Mellon Corp bought a new position in Transcat during the 4th quarter valued at about $227,000. Finally, First Trust Advisors LP lifted its stake in Transcat by 18.7% during the 4th quarter. First Trust Advisors LP now owns 12,203 shares of the scientific and technical instruments company’s stock valued at $232,000 after acquiring an additional 1,923 shares during the period. 61.21% of the stock is currently owned by institutional investors.
Separately, Zacks Investment Research upgraded shares of Acceleron Pharma from a “sell” rating to a “hold” rating in a report on Saturday, May 25th.
Transcat Company Profile
Transcat, Inc provides calibration and laboratory instrument services in North America and internationally. It operates in two segments, Service and Distribution. The Service segment offers calibration, repair, inspection, analytical qualification, preventative maintenance, consulting, and other related services.
Read More: Google Finance Portfolio
Receive News & Ratings for Transcat Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Transcat and related companies with MarketBeat.com's FREE daily email newsletter.